Georgiamune Closes $75M Series A Financing
Summary
Georgiamune Inc., a Gaithersburg, Md.-based clinical stage biotechnology company working in the fields of oncology and autoimmune diseases, completed a $75M Series A financing. General Catalyst and Parker Institute for Cancer Immunotherapy (PICI) co-led the round. Led by Founder and Chief Executive Officer Dr. Samir Khleif, Georgiamune is a clinical stage science and discovery biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company will initiate a first-in-human, open-label, phase 1/2 dose-escalation with enrichment and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and antitumor activity of GIM-122 as a single agent in adults with advanced solid malignancies who have failed treatment with a checkpoint inhibitor. Georgiamune plans to initiate its phase 1/2 clinical trial in the second half of 2023 and continue development of its extensive first-in-class pipeline for cancer and autoimmune diseases with high unmet needs.